A Citizen’s Pathway Gone Astray –Delaying Competition from Generic Drugs

Screen Shot 2017-04-27 at 4.51.03 PM

Credit

In a commentary in the New England Journal of Medicine, Robin Feldman and Connie Wang write that pharmaceutical companies have become adept at converting regulatory pathways into vehicles for profit-boosting strategies.  They study the “citizen-petition process” that the Food and Drug Administration implemented in the 1970s to give the average citizen a way to voice concerns.  Using 12 years of FDA data, they found that the “concerned citizen” is frequently a drug company raising frivolous or questionable claims in a last-ditch effort to hold off competition.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s